These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31388629)

  • 21. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
    Sanyal AJ; Ratziu V; Loomba R; Anstee QM; Kowdley KV; Rinella ME; Sheikh MY; Trotter JF; Knapple W; Lawitz EJ; Abdelmalek MF; Newsome PN; Boursier J; Mathurin P; Dufour JF; Berrey MM; Shiff SJ; Sawhney S; Capozza T; Leyva R; Harrison SA; Younossi ZM
    J Hepatol; 2023 Nov; 79(5):1110-1120. PubMed ID: 37517454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease.
    Abenavoli L; Falalyeyeva T; Boccuto L; Tsyryuk O; Kobyliak N
    Pharmaceuticals (Basel); 2018 Oct; 11(4):. PubMed ID: 30314377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved.
    Yoneda M; Kobayashi T; Wada N; Otani T; Nogami A; Iwaki M; Nakajima A
    Hepatobiliary Surg Nutr; 2023 Oct; 12(5):759-762. PubMed ID: 37886193
    [No Abstract]   [Full Text] [Related]  

  • 24. Recent advances in the development of farnesoid X receptor agonists.
    Ali AH; Carey EJ; Lindor KD
    Ann Transl Med; 2015 Jan; 3(1):5. PubMed ID: 25705637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational design of FXR agonists: a computational approach for NASH therapy.
    Gandhe A; Kumari S; Elizabeth Sobhia M
    Mol Divers; 2023 Dec; ():. PubMed ID: 38055145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
    Liu SY; Huang CC; Yang YY; Huang SF; Lee TY; Li TH; Hou MC; Lin HC
    PLoS One; 2022; 17(12):e0276717. PubMed ID: 36490253
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid.
    Wang K; Zhang Y; Wang G; Hao H; Wang H
    Med Res Rev; 2024 Mar; 44(2):568-586. PubMed ID: 37899676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
    Venetsanaki V; Karabouta Z; Polyzos SA
    Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
    Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea.
    Camilleri M; Nord SL; Burton D; Oduyebo I; Zhang Y; Chen J; Im K; Bhad P; Badman MK; Sanders DS; Walters JRF
    Aliment Pharmacol Ther; 2020 Sep; 52(5):808-820. PubMed ID: 32702169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis.
    Mo C; Xu X; Zhang P; Peng Y; Zhao X; Chen S; Guo F; Xiong Y; Chu XJ; Xu X
    J Med Chem; 2023 Jul; 66(14):9363-9375. PubMed ID: 37424079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor.
    Jiang L; Xiao D; Li Y; Dai S; Qu L; Chen X; Guo M; Wei H; Chen Y
    Biochem Biophys Res Commun; 2021 Jan; 534():1047-1052. PubMed ID: 33121679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.
    Sanyal AJ; Lopez P; Lawitz EJ; Lucas KJ; Loeffler J; Kim W; Goh GBB; Huang JF; Serra C; Andreone P; Chen YC; Hsia SH; Ratziu V; Aizenberg D; Tobita H; Sheikh AM; Vierling JM; Kim YJ; Hyogo H; Tai D; Goodman Z; Schaefer F; Carbarns IRI; Lamle S; Martic M; Naoumov NV; Brass CA
    Nat Med; 2023 Feb; 29(2):392-400. PubMed ID: 36797481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice.
    Rodrigues PM; Afonso MB; Simão AL; Carvalho CC; Trindade A; Duarte A; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM; Castro RE
    Cell Death Dis; 2017 Apr; 8(4):e2748. PubMed ID: 28406477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease.
    Fiorucci S; Biagioli M; Baldoni M; Ricci P; Sepe V; Zampella A; Distrutti E
    Expert Opin Drug Discov; 2021 Oct; 16(10):1193-1208. PubMed ID: 33849361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
    Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging therapies for the treatment of nonalcoholic steatohepatitis: A systematic review.
    Guirguis E; Grace Y; Bolson A; DellaVecchia MJ; Ruble M
    Pharmacotherapy; 2021 Mar; 41(3):315-328. PubMed ID: 33278029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
    Fiorucci S; Di Giorgio C; Distrutti E
    Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.
    Boland ML; Oldham S; Boland BB; Will S; Lapointe JM; Guionaud S; Rhodes CJ; Trevaskis JL
    World J Gastroenterol; 2018 Apr; 24(16):1748-1765. PubMed ID: 29713129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.